The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The first 3500 years of aspirin history from its roots – A concise summary
Abstract
Aspirin is currently the most widely used drug worldwide, and has been clearly one of the most important pharmacological achievements of the twentieth century. Historians of medicine have traced its birth in 1897, but the fascinating history of aspirin actually dates back >3500 years, when willow bark was used as a painkiller and antipyretic by Sumerians and Egyptians, and then by great physicians from ancient Greece and Rome. The modern history of aspirin precursors, salicylates, began in 1763 with Reverend Stone - who first described their antipyretic effects - and continued in the 19th century with many researchers involved in their extraction and chemical synthesis. Bayer chemist Felix Hoffmann synthesized aspirin in 1897, and 70 years later the pharmacologist John Vane elucidated its mechanism of action in inhibiting prostaglandin production. Originally used as an antipyretic and anti-inflammatory drug, aspirin then became, for its antiplatelet properties, a milestone in preventing cardiovascular and cerebrovascular diseases. The aspirin story continues today with the growing evidence of its chemopreventive effect against colorectal and other types of cancer, now awaiting the results of ongoing primary prevention trials in this setting. This concise review revisits the history of aspirin with a focus on its most remote origins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal
BORN, G. V. R. (1962) · Nature · doi:10.1038/194927b0 · Cited by 4,294
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.
Hamberg, M., Svensson, J., & Samuelsson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.2994 · Cited by 3,045
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.018 · Cited by 1,772
Lewis, H. D., Davis, J. W., Archibald, D. G., Steinke, W. E., Smitherman, T. C., Doherty, J. E., Schnaper, H. W., LeWinter, M. M., Linares, E., Pouget, J. M., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308183090703 · Cited by 1,709
Effects of aspirin for primary prevention in persons with diabetes mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804988 · Cited by 1,200
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened Stroke
The Canadian Cooperative Study Group (1978) · New England Journal of Medicine · doi:10.1056/nejm197807132990201 · Cited by 957
Patrignani, P., Filabozzi, P., & Patrono, C. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110576 · Cited by 937
Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., Howard, G., Pearson, T. A., Rothwell, P. M., Ruilope, L. M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31924-x · Cited by 883
Release of Additional Factors in Anaphylaxis and its Antagonism by Anti-inflammatory Drugs
PIPER, P. J., & VANE, J. R. (1969) · Nature · doi:10.1038/223029a0 · Cited by 880
Bibbins-Domingo, K., & on behalf of the U.S. Preventive Services Task Force* (2016) · Annals of Internal Medicine · doi:10.7326/m16-0577 · Cited by 854
Algra, A. M., & Rothwell, P. M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70112-2 · Cited by 831
(1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251801 · Cited by 759
Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis
Roberge, S., Bujold, E., & Nicolaides, K. H. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.11.561 · Cited by 628
The Salt Collaborative Group (1991) · The Lancet · doi:10.1016/0140-6736(91)92233-r · Cited by 553
Elwood, P. C., Cochrane, A., Burr, M. L., Sweetnam, P. M., Williams, G., Welsby, E., Hughes, S. J., & Renton, R. (1974) · BMJ · doi:10.1136/bmj.1.5905.436 · Cited by 519
Hemler, M., & Lands, W. E. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33098-3 · Cited by 437
Anti-inflammatory effects of aspirin and sodium salicylate
Amann, R., & Peskar, B. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01828-9 · Cited by 372
Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin.
Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., & Smith, W. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36820-5 · Cited by 371
Rothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31133-4 · Cited by 353
The aspirin story – from willow to wonder drug
Desborough, M. J. R., & Keeling, D. M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14520 · Cited by 328
Sneader, W. (2005) · Cited by 302
Patrignani, P., & Patrono, C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.083 · Cited by 257
Jack, D. B. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07087-6 · Cited by 256
The discovery of aspirin: a reappraisal
Sneader, W. (2000) · BMJ · doi:10.1136/bmj.321.7276.1591 · Cited by 249
Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
Ornelas, A., Zacharias-Millward, N., Menter, D. G., Davis, J. S., Lichtenberger, L., Hawke, D., Hawk, E., Vilar, E., Bhattacharya, P., & Millward, S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9675-z · Cited by 225
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J.-P., Fitzgerald, D., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 221
Aspirin for Prevention of Preeclampsia
Atallah, A., Lecarpentier, E., Goffinet, F., Doret-Dion, M., Gaucherand, P., & Tsatsaris, V. (2017) · Drugs · doi:10.1007/s40265-017-0823-0 · Cited by 212
The Role of Aspirin in the Prevention of Cardiovascular Disease
Ittaman, S. V., VanWormer, J. J., & Rezkalla, S. H. (2014) · Clinical Medicine & Research · doi:10.3121/cmr.2013.1197 · Cited by 202
Peet, T. E. (1931) · The Journal of Egyptian Archaeology · doi:10.1177/030751333101700126 · Cited by 183
ANALGESIC ANTIPYRETIC DRUGS AS ANTAGONISTS OF BRADYKININ
COLLIER, H. O. J., & SHORLEY, P. G. (1960) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1960.tb00288.x · Cited by 172
Aspirin Therapy in Primary Cardiovascular Disease Prevention
Halvorsen, S., Andreotti, F., ten Berg, J. M., Cattaneo, M., Coccheri, S., Marchioli, R., Morais, J., Verheugt, F. W. A., & De Caterina, R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.049 · Cited by 166
Self-citationPharmakologisches über Aspirin (Acetylsalicylsäure)
Dreser, H. (1899) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf01662127 · Cited by 141
Nonsteroidal anti-inflammatory drugs exposure and the central nervous system
Auriel, E., Regev, K., & Korczyn, A. D. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4086-3.00038-2 · Cited by 139
Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events
Sundström, J., Hedberg, J., Thuresson, M., Aarskog, P., Johannesen, K. M., & Oldgren, J. (2017) · Circulation · doi:10.1161/circulationaha.117.028321 · Cited by 137
Ll, C. (1953) · PubMed · Cited by 132
Aspirin: The Remarkable Story of a Wonder Drug
Lidstone, J. (2005) · Journal of Medical Marketing Device Diagnostic and Pharmaceutical Marketing · doi:10.1057/palgrave.jmm.5040227 · Cited by 123
Aspirin for the Prevention of Preterm and Term Preeclampsia: Systematic Review and Meta-Analysis
Roberge, S., Bujold, E., & Nicolaides, K. H. (2018) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0000547277.94540.23 · Cited by 120
STUDIES ON THE HEMORRHAGIC SWEET CLOVER DISEASE
Link, K. P., Overman, R. S., Sullivan, W. R., et al. (1943) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)72399-5 · Cited by 115
Matthews, R. N. (1993) · Journal of the Royal Society of Medicine · Cited by 105
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90049-3 · Cited by 91
Veettil, S. K., Lim, K. G., Ching, S. M., Saokaew, S., Phisalprapa, P., & Chaiyakunapruk, N. (2017) · BMC Cancer · doi:10.1186/s12885-017-3757-8 · Cited by 85
Aspirin: The Remarkable Story of a Wonder Drug
Jeffreys, D. (2004) · Cited by 83
Aspirin after myocardial infarction
Glasziou, P. (1989) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1989.tb136344.x · Cited by 75
THE TREATMENT OF ACUTE RHEUMATISM BY SALICIN.
Maclagan, T. J. (1876) · The Lancet · doi:10.1016/s0140-6736(02)49509-8 · Cited by 69
Wood, E. (1993) · Biochemical Education · doi:10.1016/0307-4412(93)90074-a · Cited by 59
Aspirin after Myocardial Infarction
(1980) · The Lancet · doi:10.1016/s0140-6736(80)91626-8 · Cited by 52
Untersuchungen über die wasserfreien organischen Säuren
Gerhardt, C. (1853) · Justus Liebig s Annalen der Chemie · doi:10.1002/jlac.18530870107 · Cited by 47
Caterina, R. D., Giannessi, D., Bernini, W., et al. (1985) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a061879 · Cited by 44
Aspirin and lipid mediators in the cardiovascular system
Schrör, K., & Rauch, B. H. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.07.004 · Cited by 42
ASPIRIN IN THE TREATMENT OF VASCULAR DISEASES
Gibson, P. (1949) · The Lancet · doi:10.1016/s0140-6736(49)91829-2 · Cited by 42
Cited by
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Prevention of preeclampsia with aspirin
Rolnik, D. L., Nicolaides, K. H., & Poon, L. C. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.08.045 · Cited by 390
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Kulesza, A., Paczek, L., & Burdzinska, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020445 · Cited by 163
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
Metadata
- Authors
- Montinari, M. R., Minelli, S., & De Caterina, R.
- Venue
- Vascular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 113
- Pages
- 1-8
- ISSN
- 1537-1891 (ISSN-L)
- OpenAlex
- W2899349918
- Cited by
- 315
- References
- 60
- FWCI
- 10.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.